These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 7949207

  • 21. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients.
    Dowsett M, Cunningham DC, Stein RC, Evans S, Dehennin L, Hedley A, Coombes RC.
    Cancer Res; 1989 Mar 01; 49(5):1306-12. PubMed ID: 2917360
    [Abstract] [Full Text] [Related]

  • 22. Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study.
    Höffken K, Jonat W, Possinger K, Kölbel M, Kunz T, Wagner H, Becher R, Callies R, Friederich P, Willmanns W.
    J Clin Oncol; 1990 May 01; 8(5):875-80. PubMed ID: 2185341
    [Abstract] [Full Text] [Related]

  • 23. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study.
    Celio L, Martinetti A, Ferrari L, Buzzoni R, Mariani L, Miceli R, Seregni E, Procopio G, Cassata A, Bombardieri E, Bajetta E.
    Anticancer Res; 1999 May 01; 19(3B):2261-8. PubMed ID: 10472341
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Aromatase and its inhibitors in breast cancer treatment--overview and perspective.
    Brodie AM, Santen RJ.
    Breast Cancer Res Treat; 1994 May 01; 30(1):1-6. PubMed ID: 7949200
    [Abstract] [Full Text] [Related]

  • 26. 4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer.
    Coombes RC, Goss PE, Dowsett M, Hutchinson G, Cunningham D, Jarman M, Brodie AM.
    Steroids; 1987 May 01; 50(1-3):245-52. PubMed ID: 3504062
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and tolerability of 4-hydroxyandrostenedione (4-OHA) as first-line treatment in postmenopausal patients with breast cancer after adjuvant therapy.
    Bajetta E, Zilembo N, Buzzoni R, Noberasco C, Celio L, Bichisao E.
    Cancer Treat Rev; 1993 Apr 01; 19 Suppl B():31-6. PubMed ID: 8481932
    [Abstract] [Full Text] [Related]

  • 28. Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione.
    Stein RC, Dowsett M, Hedley A, Davenport J, Gazet JC, Ford HT, Coombes RC.
    Cancer Chemother Pharmacol; 1990 Apr 01; 26(1):75-8. PubMed ID: 2322991
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. 4-Hydroxyandrostenedione treatment for postmenopausal patients with breast cancer.
    Coombes RC.
    J Steroid Biochem Mol Biol; 1992 Sep 01; 43(1-3):145-8. PubMed ID: 1525056
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Clinical development of aromatase inhibitors for the treatment of breast and prostate cancer.
    Dowsett M.
    J Steroid Biochem Mol Biol; 1990 Dec 20; 37(6):1037-41. PubMed ID: 2149504
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Formestane in the treatment of advanced postmenopausal breast cancer.
    Possinger K, Jonat W, Höffken K.
    Ann Oncol; 1994 Dec 20; 5 Suppl 7():S7-10. PubMed ID: 7873464
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.